BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...analysis division; Moreno was CSO of Wamberg Genomic Advisors. Cradle is developing fetal genetic analyses. MannKind...
...was VP and president of the advanced insulin management business unit of Medtronic plc (NYSE:MDT). MannKind...
...Inc. Rhythm Pharmaceuticals Kronos Bio Inc. ImmunoGen Inc. Akcea Therapeutics Inc. Circle Pharma Inc. Antares Pharma Inc. Krystal Biotech Inc. BioSpecifics Technologies Corp. Cradle Genomics MannKind...
BioCentury | Sep 16, 2019
Company News

Sept. 16 Company Quick Takes: FDA accepts Seattle Genetics' BLA; plus Akynzeo, Purdue, Amplyx, Abbott-Sanofi

...approves Akynzeo for CINV China’s National Medical Products Administration approved the oral formulation of Akynzeo netupitant/palonosetron...
...therapy is a fixed-dose combination of 300 mg netupitant, a NK1R antagonist, and 0.5 mg palonosetron...
BioCentury | Jan 23, 2019
Politics & Policy

SCOTUS upholds lower court's ruling in Helsinn patent case

...for infringing its U.S. Patent No. 8,598,219 for a fixed 0.25 mg dose of Aloxi palonosetron...
...vomiting. Aloxi received its first U.S. approval in 2003. Teva launched its generic version of Aloxi...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Sep 7, 2018
Company News

MannKind stock climbs after closing treprostinil deal with United Therapeutics

...4 after signing a deal with United Therapeutics Corp. (NASDAQ:UTHR) for rights to Treprostinil Technosphere. MannKind...
...United Therapeutics gains an exclusive, worldwide license to the dry powder formulation of treprostinil, which MannKind...
...prostacyclin analog. United Therapeutics will be responsible for global development and regulatory and commercial activities. MannKind...
BioCentury | Apr 13, 2018
Financial News

MannKind raises $28M in registered direct offering

...agent. The April 6 stock move represented a loss in market cap of $78.5 million. MannKind...
...October (see BioCentury, Oct. 13, 2017) . MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD), Westlake Village, Calif. Jennie Walters MannKind...
BioCentury | Feb 8, 2018
Company News

Management tracks: CRISPR, Arcturus

...Tokyo:4503) said VP of Corporate Planning Naoki Okamura will become chief strategy officer. Diabetes company MannKind...
BioCentury | Oct 13, 2017
Financial News

MannKind raises $61M registered direct offering

...On Oct. 11, inhaled insulin company MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD) raised $61 million through the...
...at $6 in a registered direct offering. MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD), Westlake Village, Calif. Jennie Walters MannKind...
BioCentury | Jul 13, 2017
Targets & Mechanisms

Insider signaling

...vomiting (CINV): Merck & Co. Inc. ’s Emend fosaprepitant dimeglumine, Helsinn Healthcare S.A. ’s Akynzeo netupitant/palonosetron...
BioCentury | Jun 22, 2017
Translation in Brief

TERS talk

...involved. At least four companies are pursuing targets Zanetti's group showed are involved in TERS. Mannkind...
...protein response promotes survival and drug resistance in cancer cells." Science Signaling (2017) Michael Leviten, Senior Writer MannKind...
Items per page:
1 - 10 of 525